منابع مشابه
Targeting osteosarcoma.
Small-molecule targeted therapies have significantly improved the treatment landscape for many cancers. When a patient’s tumor expresses the protein kinase BCR-ABL or the protein kinase BRAFV600E, or overexpresses the androgen receptor, we now know what to do: treat with the corresponding small molecule that targets the driver oncogene. However, in a so-called “orphan cancer” such as osteosarco...
متن کاملTargeting the osteosarcoma cancer stem cell
Osteosarcoma is the most common type of solid bone cancer and the second leading cause of cancer-related death in pediatric patients. Many patients are not cured by the current osteosarcoma therapy consisting of combination chemotherapy along with surgery and thus new treatments are urgently needed. In the last decade, cancer stem cells have been identified in many tumors such as leukemia, brai...
متن کاملEngineered Nanomedicine with Alendronic Acid Corona Improves Targeting to Osteosarcoma
We engineered nanomedicine with the stealth corona made up of densely packed bone seeking ligand, alendronic acid. In a typical nanoconstruct, alendronic acid is conjugated with hydrophilic head moiety of phospholipid that has an ability to self-assemble with hydrophobic polymeric core through its hydrophobic long carbon-chain. Proposed nanomedicine has three distinct compartments namely; poly(...
متن کاملMALAT1 promotes osteosarcoma development by targeting TGFA via MIR376A
Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a long non-coding RNA (lncRNA) that contributes to the initiation and development of many solid tumors, including osteosarcoma (OS). Here, we showed that MALAT1 was increased in human OS cell lines and tissues and promoted OS cell growth, while MALAT1 knockdown suppressed OS cell growth. We also detected downregulation of MIR376...
متن کاملTargeting JNK-interacting protein 1 (JIP1) sensitises osteosarcoma to doxorubicin
Osteosarcoma (OS) is the most common primary malignant bone tumour in children and adolescents. Despite aggressive therapy, survival outcomes remain unsatisfactory, especially for patients with metastatic disease or patients with a poor chemotherapy response. Chemoresistance contributes to treatment failure. To increase the efficacy of conventional chemotherapy, essential survival pathways shou...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Proceedings of the National Academy of Sciences
سال: 2014
ISSN: 0027-8424,1091-6490
DOI: 10.1073/pnas.1420596111